Clinical practice guidelines for the use of parathyroid hormone in the treatment of osteoporosis
Authors:
- Anthony HodsmanAHAnthony Hodsman
- Alexandra PapaioannouAPAlexandra Papaioannou
- Ann CranneyACAnn Cranney
Open Access
- 4 July 2006
- journal article
- editorial
- Published by CMA Impact Inc. in Canadian Medical Association Journal
- Vol. 175 (1) , 48
Abstract
In 2002, Osteoporosis Canada published clinical practice guidelines for the diagnosis and management of osteoporosis in Canada.[1][1] At the time, there was considerable evidence for the use of anti-resorptive agents in the management of osteoporosis, including estrogen, the selective estrogenKeywords
This publication has 15 references indexed in Scilit:
- Advances in Male ContraceptionEndocrine Reviews, 2008
- Parathyroid hormone for the treatment of osteoporosis: a systematic reviewCanadian Medical Association Journal, 2006
- Correlates of health-related quality of life in type 2 diabetesDiabetologia, 2006
- Parathyroid Hormone and Teriparatide for the Treatment of Osteoporosis: A Review of the Evidence and Suggested Guidelines for Its UseEndocrine Reviews, 2005
- 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada.2002
- Odds Ratio, Relative Risk, Absolute Risk Reduction, and the Number Needed to Treat—Which of These Should We Use?Value in Health, 2002
- Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with OsteoporosisNew England Journal of Medicine, 2001
- Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal OsteoporosisOsteoporosis International, 2000
- Effects of Risedronate Treatment on Vertebral and Nonvertebral Fractures in Women With Postmenopausal OsteoporosisA Randomized Controlled TrialJAMA, 1999
- Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fracturesThe Lancet, 1996